Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649698 | 0.91 | RAB9A (0.43) | NPC1RAB9AATMSCD5NAMPT | |
| SCHEMBL3688733 | 0.91 | SCD5 (0.47) | NPC1RAB9AATMSCD5RBP4 | |
| SCHEMBL3688390 | 0.89 | NPC1 (0.42) | NPC1RAB9AATMSCD5HSD11B1 | |
| SCHEMBL3692042 | 0.85 | SCD5 (0.43) | NPC1RAB9AATMSCD5HSD11B1 | |
| SCHEMBL3701088 | 0.85 | NPC1 (0.44) | NPC1RAB9AATMSCD5HSD11B1 | |
| SCHEMBL3686875 | 0.84 | SCD5 (0.40) | NPC1RAB9AATMSCD5HSD11B1 | |
| SCHEMBL3690972 | 0.83 | PROKR1 (0.44) | NPC1RAB9AATMSCD5HSD11B1 | |
| SCHEMBL3694395 | 0.83 | SCD5 (0.45) | NPC1RAB9AATMSCD5HSD11B1 | |
| SCHEMBL3687356 | 0.83 | SCD5 (0.50) | NPC1RAB9AATMSCD5CYP3A4 | |
| SCHEMBL3650369 | 0.81 | SCD5 (0.46) | NPC1RAB9AATMSCD5NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| CN-101842098-A | Nitrogen-containing bicyclic chemical entities for the treatment of viral infections | GENELABS TECH INC | 2010-09-22 | — | — | CN | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | NPC1 229/4885RAB9A 3638/4885ATM 4319/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | NPC1 229/4885RAB9A 3638/4885ATM 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.